Currently, there are few therapeutic alternatives for AD (donanemab, lecanemab, aducanumab, donepezil, rivastigmine, galantamine, and memantine) . However, multiple clinical trials (Phase I -IV) of different drugs and bioactive compounds are being carried out . Among the drug-targets in clinical trials, a polypharmacological profile can be observed. For instance, vorinostat (histone deacetylase (HDAC) inhibitor), an FDA-approved drug indicated for the treatment of cutaneous manifestations in patients with T-cell lymphoma has proven to reverse memory deficits in a mouse model with AD ; therefore, it is being repositioned as anti-AD (ClinicalTrials.gov Identifier: NCT03056495). Dasatinib (tyrosine kinase inhibitor) is currently approved for the treatment of lymphoblastic or chronic myeloid leukemia ; however, its effects on neuroinflammation mediated by microglial and/or astrocytic responses has led to testing its effect in modulating AD progression (ClinicalTrials.gov Identifier: NCT04063124). Polypharamacological profiles of drug/targets could be used for drug repurposing, identifying, and validating new targets, and finding new bioactive ligands, among other applications.